(Bloomberg) — Eli Lilly & Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by the blockbuster weight-loss drug Zepbound.
Most Read from Bloomberg
The company also raised its quarterly dividend 15%, according to a statement Monday. The shares rose as much as 1.3% in late trading after the US markets closed.
The share repurchases may be made from time to time at management’s discretion, Lilly said.
Most Read from Bloomberg Businessweek
©2024 Bloomberg L.P.
